Skip to main content
. 2010 Nov 10;2010(11):CD005197. doi: 10.1002/14651858.CD005197.pub3

Comparison 2. Ceftazidime vs. other.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 All‐cause mortality 19 3335 Risk Ratio (M‐H, Fixed, 95% CI) 0.81 [0.59, 1.13]
1.1 cefepime 10 1146 Risk Ratio (M‐H, Fixed, 95% CI) 0.66 [0.43, 1.01]
1.2 carbapenem 8 2028 Risk Ratio (M‐H, Fixed, 95% CI) 1.10 [0.65, 1.86]
1.3 piperacillin‐tazobactam 1 161 Risk Ratio (M‐H, Fixed, 95% CI) 1.18 [0.07, 18.47]
2 Infection related mortality 17 3476 Risk Ratio (M‐H, Fixed, 95% CI) 0.95 [0.62, 1.46]
2.1 cefepime 7 951 Risk Ratio (M‐H, Fixed, 95% CI) 0.91 [0.48, 1.73]
2.2 carbapenem 8 2025 Risk Ratio (M‐H, Fixed, 95% CI) 1.05 [0.54, 2.04]
2.3 piperacillin 1 339 Risk Ratio (M‐H, Fixed, 95% CI) 0.73 [0.20, 2.68]
2.4 piperacillin‐tazobactam 1 161 Risk Ratio (M‐H, Fixed, 95% CI) 1.18 [0.07, 18.47]
3 Clinical failure 21 4204 Risk Ratio (M‐H, Fixed, 95% CI) 1.04 [0.98, 1.10]
3.1 cefepime 9 1087 Risk Ratio (M‐H, Fixed, 95% CI) 1.00 [0.92, 1.09]
3.2 carbapenem 9 2340 Risk Ratio (M‐H, Fixed, 95% CI) 1.16 [1.07, 1.26]
3.3 ticarcillin‐clavulanate 1 312 Risk Ratio (M‐H, Fixed, 95% CI) 0.79 [0.53, 1.17]
3.4 piperacillin 1 304 Risk Ratio (M‐H, Fixed, 95% CI) 0.54 [0.38, 0.78]
3.5 piperacillin‐tazobactam 1 161 Risk Ratio (M‐H, Fixed, 95% CI) 0.95 [0.68, 1.33]
4 Clinical failure ‐ sensitivity analysis allocation concealment 21 4204 Risk Ratio (M‐H, Fixed, 95% CI) 1.04 [0.98, 1.10]
4.1 adequate 10 1743 Risk Ratio (M‐H, Fixed, 95% CI) 1.01 [0.93, 1.10]
4.2 unclear 11 2461 Risk Ratio (M‐H, Fixed, 95% CI) 1.06 [0.98, 1.15]
5 Clinical failure ‐ sensitivity analysis allocation generation 21 4204 Risk Ratio (M‐H, Fixed, 95% CI) 1.04 [0.98, 1.10]
5.1 adequate 14 2837 Risk Ratio (M‐H, Fixed, 95% CI) 1.01 [0.93, 1.09]
5.2 unclear 6 1327 Risk Ratio (M‐H, Fixed, 95% CI) 1.09 [1.00, 1.19]
5.3 inadequate 1 40 Risk Ratio (M‐H, Fixed, 95% CI) 1.13 [0.55, 2.32]
6 Microbiological failure 18 1166 Risk Ratio (M‐H, Fixed, 95% CI) 0.94 [0.85, 1.04]
6.1 cefepime 7 225 Risk Ratio (M‐H, Fixed, 95% CI) 1.07 [0.86, 1.34]
6.2 carbapenem 8 633 Risk Ratio (M‐H, Fixed, 95% CI) 1.02 [0.91, 1.15]
6.3 ticarcillin‐clavulanate 1 104 Risk Ratio (M‐H, Fixed, 95% CI) 0.51 [0.22, 1.22]
6.4 piperacillin 1 110 Risk Ratio (M‐H, Fixed, 95% CI) 0.25 [0.10, 0.59]
6.5 piperacillin‐tazobactam 1 94 Risk Ratio (M‐H, Fixed, 95% CI) 0.83 [0.54, 1.28]
7 Any modifications 15 2527 Risk Ratio (M‐H, Fixed, 95% CI) 1.10 [1.02, 1.18]
7.1 cefepime 7 712 Risk Ratio (M‐H, Fixed, 95% CI) 1.00 [0.86, 1.15]
7.2 carbapenem 7 1654 Risk Ratio (M‐H, Fixed, 95% CI) 1.16 [1.07, 1.26]
7.3 piperacillin‐tazobactam 1 161 Risk Ratio (M‐H, Fixed, 95% CI) 0.95 [0.68, 1.33]
8 Glycopeptide addition 12 2221 Risk Ratio (M‐H, Fixed, 95% CI) 1.21 [1.05, 1.41]
8.1 cefepime 5 631 Risk Ratio (M‐H, Fixed, 95% CI) 1.01 [0.77, 1.33]
8.2 carbapenem 6 1429 Risk Ratio (M‐H, Fixed, 95% CI) 1.43 [1.17, 1.76]
8.3 piperacillin‐tazobactam 1 161 Risk Ratio (M‐H, Fixed, 95% CI) 0.95 [0.68, 1.33]
9 Antifungal drug addition 10 2012 Risk Ratio (M‐H, Fixed, 95% CI) 0.91 [0.73, 1.14]
9.1 cefepime 4 527 Risk Ratio (M‐H, Fixed, 95% CI) 0.90 [0.61, 1.32]
9.2 carbapenem 6 1485 Risk Ratio (M‐H, Fixed, 95% CI) 0.92 [0.70, 1.21]
10 Superinfection ‐ any 12 2783 Risk Ratio (M‐H, Fixed, 95% CI) 1.20 [0.95, 1.52]
10.1 cefepime 5 568 Risk Ratio (M‐H, Fixed, 95% CI) 1.14 [0.68, 1.93]
10.2 carbapenem 5 1578 Risk Ratio (M‐H, Fixed, 95% CI) 1.21 [0.91, 1.60]
10.3 ticarcillin‐clavulanate 1 312 Risk Ratio (M‐H, Fixed, 95% CI) 0.85 [0.27, 2.70]
10.4 piperacillin 1 325 Risk Ratio (M‐H, Fixed, 95% CI) 1.67 [0.64, 4.35]
11 Superinfection ‐ bacterial 4 987 Risk Ratio (M‐H, Fixed, 95% CI) 0.58 [0.26, 1.31]
11.1 cefepime 2 284 Risk Ratio (M‐H, Fixed, 95% CI) 0.53 [0.14, 2.04]
11.2 carbapenem 1 378 Risk Ratio (M‐H, Fixed, 95% CI) 0.54 [0.10, 2.90]
11.3 piperacillin 1 325 Risk Ratio (M‐H, Fixed, 95% CI) 0.67 [0.18, 2.45]
12 Adverse events ‐ any 11   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
12.1 cefepime 6 745 Risk Ratio (M‐H, Fixed, 95% CI) 1.04 [0.94, 1.15]
12.2 carbapenem 3 1118 Risk Ratio (M‐H, Fixed, 95% CI) 0.43 [0.31, 0.60]
12.3 ticarcillin‐clavulanate 1 312 Risk Ratio (M‐H, Fixed, 95% CI) 1.49 [0.57, 3.89]
12.4 piperacillin 1 339 Risk Ratio (M‐H, Fixed, 95% CI) 0.30 [0.15, 0.58]
13 Adverse events requiring discontinuation 14 2384 Risk Ratio (M‐H, Fixed, 95% CI) 0.69 [0.47, 1.03]
13.1 cefepime 8 1062 Risk Ratio (M‐H, Fixed, 95% CI) 0.65 [0.39, 1.09]
13.2 carbapenem 6 1322 Risk Ratio (M‐H, Fixed, 95% CI) 0.76 [0.41, 1.41]